HC Wainwright & Co. Downgrades Vascular Biogenics to Neutral
HC Wainwright & Co. analyst Swayampakula Ramakanth downgrades Vascular Biogenics (NASDAQ:VBLT) from Buy to Neutral.
Vascular Biogenics Granted U.S. Patent #EP3441089 Titled “TREATMENT METHODS USING ADENOVIRUS (TO REDUCE, DECREASE THE SIZE OF, OR ELIMINATE A TUMOR)”
About this file - European Patent Register (epo.org)
The Daily Biotech Pulse: Pfizer-BioNTech’s COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio’s AP-013 Trial Under Independent Investigation
Here's a roundup of top developments in the biotech space over the last 24 hours:
Vascular Biogenics Q1 EPS $(0.13) Misses $(0.11) Estimate, Sales $113.00K Miss $200.00K Estimate
Vascular Biogenics (NASDAQ:VBLT) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.11) by 18.18 percent. This is a 8.33 percent decrease over losses of $(0.12) per share
Earnings Scheduled For May 17, 2022
Companies Reporting Before The Bell
• On Holding (NYSE:ONON) is likely to report earnings for its first quarter.
The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More
Biopharma stocks remained largely unchanged in the week ending May 13, with the defensive nature of the sector coming to its aid. Stocks reacted to the broader market move and earnings news from mid-cap companies.
Chardan Capital Initiates Coverage On Vascular Biogenics with Buy Rating, Announces Price Target of $5
Chardan Capital analyst Matthew Barcus initiates coverage on Vascular Biogenics (NASDAQ:VBLT) with a Buy rating and announces Price Target of $5.
U.S. FDA Grants Fast Track designation To Ofra-Vec (VB-111) For Platinum-Resistant Ovarian Cancer
VBL Therapeutics (NASDAQ: VBLT) received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its drug candidate Ofra-Vec (VB-111) in combination with Paclitaxel for the treatment of patients with platinum-resistant ovarian cancer.
The Daily Biotech Pulse: Protagonist’s Ulcerative Colitis Study Disappoints, Gilead’s Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida’s Cell Therapy Trial, Fast Track Tag For Vascular Biogenics Ovarian Cancer Gene Therapy
Here's a roundup of top developments in the biotech space over the last 24 hours:
Earnings Scheduled For March 23, 2022
Companies Reporting Before The Bell
• AYRO (NASDAQ:AYRO) is expected to report earnings for its fourth quarter.